What is the clinical impact of a forced expiratory flow (FEF 25‑75) that is 16% of predicted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Impact of FEF 25-75 at 16% of Predicted

An FEF 25-75 of 16% predicted indicates severe small airway obstruction and is associated with significantly worse clinical outcomes, including increased risk of exacerbations, more severe disease, and greater symptom burden, though this primarily reflects overall airflow obstruction severity rather than representing an independent risk factor.

Understanding the Severity

A value of 16% predicted places this patient in the most severely impaired category. In the KOCOSS cohort study, patients with FEF 25-75 ≤17% predicted (Q4, the lowest quartile) experienced:

  • 81.1% had at least one moderate-to-severe exacerbation over 3 years (compared to 54% in the highest quartile)
  • Mean cumulative exacerbation count of 5.8 (compared to 2.0 in the highest quartile)
  • 2.67 times higher risk of exacerbations in clinical models 1

Clinical Interpretation Framework

Primary Consideration: Overall Airflow Obstruction

The critical finding from recent research is that the prognostic value of severely reduced FEF 25-75 is predominantly explained by FEV1-defined airflow obstruction severity 1. When adjusted for FEV1, the independent association with exacerbations becomes non-significant. This means:

  • FEF 25-75 at 16% should be interpreted as a marker of overall physiological impairment rather than isolated small airway disease
  • Check the FEV1 value—this will be the primary driver of clinical outcomes
  • The European Respiratory Society guidelines confirm that abnormalities in mid-range flow measurements "are not specific for small airway disease in individual patients" 2

Associated Clinical Features at This Severity Level

Based on SPIROMICS cohort data, FEF 25-75 at this level correlates with 3:

  • Increased emphysema (particularly homogeneous distribution)
  • Greater functional small airways disease on CT imaging
  • Increased air trapping (elevated residual volume and total lung capacity)
  • Thicker airway walls on CT
  • Increased bronchodilator responsiveness
  • More severe symptoms and decreased exercise capacity (reduced 6-minute walk distance)

Disease-Specific Implications

In COPD Patients

  • Expect higher exacerbation burden over time
  • Reflects loss of elastic recoil and air trapping from emphysema combined with intrinsic small airways disease 3
  • The severity classification should be based on FEV1, not FEF 25-75 alone 2

In Asthma Patients

The implications differ somewhat from COPD:

  • In children with asthma and normal FEV1, low FEF 25-75 is associated with:
    • 6 times higher odds of asthma exacerbations 4
    • 2.8 times higher odds of systemic corticosteroid use 4
    • Increased asthma severity 4
  • Predicts long-term asthma persistence over 20 years, particularly in children 5
  • Associated with more severe bronchial hyperresponsiveness 5

In Allergic Rhinitis Without Overt Asthma

Even at 16% predicted in patients without asthma symptoms, this suggests:

  • Early bronchial involvement and subclinical airway dysfunction 6
  • Higher likelihood of positive bronchial hyperresponsiveness testing 6
  • May represent progression toward asthma

Bronchodilator Response Considerations

Using FEF 25-75 to assess bronchodilator response identifies 53% more patients with reversible obstruction than FEV1 alone 4. The guidelines recommend:

  • A >12% and >200 mL change in FEV1 or FVC indicates significant bronchodilation 2
  • FEF 25-75 is highly variable and depends on FVC, which increases with expiratory time in obstructed patients 2
  • If FEV1 doesn't show significant response, decreased lung hyperinflation may still indicate meaningful bronchodilation 2

Common Pitfalls to Avoid

  1. Don't interpret FEF 25-75 in isolation: Always correlate with FEV1, FVC, and FEV1/FVC ratio 2, 1

  2. Don't assume isolated small airway disease: At 16% predicted, this reflects widespread airflow obstruction, not just small airways 1

  3. Don't use FEF 25-75 for severity staging: Use FEV1 % predicted for COPD severity classification 2

  4. Don't dismiss normal FEV1 if FEF 25-75 is low: In asthma particularly, this combination warrants closer monitoring and more aggressive management 4, 7

Practical Clinical Actions

For a patient with FEF 25-75 at 16% predicted:

  • Optimize bronchodilator therapy and assess response using both FEV1 and symptoms
  • Anticipate higher exacerbation risk and consider more aggressive preventive strategies
  • Evaluate for emphysema and air trapping with CT imaging if not already done
  • Monitor closely for disease progression, especially in asthma patients with normal FEV1
  • Consider pulmonary rehabilitation given the association with reduced exercise capacity 3
  • Assess and address modifiable risk factors (smoking cessation, allergen avoidance, adherence to controller medications)

References

2
Guideline

interpretative strategies for lung function tests.

European Respiratory Journal, 2005

4
Research

The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity.

The Journal of asthma : official journal of the Association for the Care of Asthma, 2012

6
Research

Reduced forced expiratory flow between 25% and 75% of vital capacity in children with allergic rhinitis without asthmatic symptoms.

The Journal of asthma : official journal of the Association for the Care of Asthma, 2023

Related Questions

What is the Forced Expiratory Flow (FEF) 25-75?
What postoperative pulmonary complications are expected in a patient with severe chronic obstructive pulmonary disease (forced expiratory volume in one second (FEV1) ~48% predicted, forced expiratory flow at 25‑75% (FEF 25‑75) ~16% predicted) after coronary artery bypass grafting?
In a patient being evaluated for suspected chronic obstructive pulmonary disease (COPD) with spirometry showing forced vital capacity (FVC) 3.34 L (111% predicted) pre‑bronchodilator and 3.43 L (114%) post‑bronchodilator, forced expiratory volume in one second (FEV1) 2.69 L (120%) pre and 2.83 L (126%) post, FEV1/FVC ratio 80.5% (107%) pre and 82.5% (109%) post, and forced expiratory flow 25‑75% (FEF25‑75) 2.82 L/s (176%) pre and 3.14 L/s (105%) post, how should these results be interpreted and what is the appropriate management?
Is there a correlation between spirometry parameters (e.g., forced expiratory flow 25‑75% and FEV1/FVC ratio) and small‑airway disease?
What is the interpretation and management of a decreased PEF25-75 (Peak Expiratory Flow 25-75) value in a patient with respiratory symptoms or known respiratory diseases such as asthma or Chronic Obstructive Pulmonary Disease (COPD)?
What is the appropriate management for an otherwise healthy adult with a fasting blood glucose of 107 mg/dL and an HbA1c of 5.26%?
What are the signs and symptoms of bleeding following a percutaneous kidney biopsy?
As an adult patient taking sertraline 100 mg daily, why am I experiencing difficulty concentrating and what steps should I take?
Can I switch from sertraline (100 mg) to escitalopram (10 mg) to avoid mental fog?
In a patient with Addison's disease, serum sodium 129 mmol/L, normal potassium, currently treated with hydrocortisone 20 mg in the morning and 10 mg in the afternoon and fludrocortisone half tablet daily, what is the appropriate next step in management?
Should a 1‑year‑11‑month‑old child with a history of febrile seizures who is coinfected with COVID‑19 and influenza B be referred to the hospital for evaluation and management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.